{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T19:51:40Z","timestamp":1786564300412,"version":"build-2736575974"},"reference-count":25,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022606","name":"Almirall","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The 31<jats:sup>st<\/jats:sup> European Academy of Dermatology and Venereology (EADV) Congress took place between 7<jats:sup>th<\/jats:sup> and 10<jats:sup>th<\/jats:sup> of September 2022 in Milan, Italy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>We report presented clinical data on the efficacy\/effectiveness, safety and tolerability of tirbanibulin 1% ointment that has recently been licensed for actinic keratosis (AK) of the face or scalp in adults.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Summary of presentations given at the EADV Congress.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Prof. Pellacani presented two post hoc analyses from two phase\u2010III trials with AK patients (NCT03285477 [<jats:italic>N<\/jats:italic>\u2009=\u2009351] and NCT03285490 [<jats:italic>N<\/jats:italic>\u2009=\u2009351]): A descriptive analysis of medical history, concomitant medications, and safety results confirming a favourable profile for tirbanibulin showing that number of baseline AK lesions was not correlated to severity of local skin reactions. The latter analysis showed that cases of tirbanibulin application site pain or pruritus were few, and most were found to be mild. Prof. Kunstfeld reported six real\u2010life clinical cases in Austria showing good tirbanibulin effectiveness, safety and tolerability for the treatment of new or recurring AK lesions. Results demonstrated that after 2\u2010 to 4\u2010month follow\u2010up, tirbanibulin was well tolerated and effective in AK patients. Presentations by Dr. Patel confirmed good outcomes and tolerability of tirbanibulin in Olsen grade 1\u20132 AK (<jats:italic>N<\/jats:italic>\u2009=\u200912) and porokeratosis patients (<jats:italic>N<\/jats:italic>\u2009=\u20094) treated once daily for 5 consecutive days in the United Kingdom. Furthermore, real\u2010world experience in solid organ transplant recipients (<jats:italic>N<\/jats:italic>\u2009=\u20092) demonstrated effectiveness of tirbanibulin in skin field cancerization treatment. A symposium sponsored by Almirall was conducted during the congress in which Dr. Hadshiew and Dr. Lear brought together their clinical experience in Germany and the United Kingdom respectively. Interesting clinical cases of 5 consecutive days of tirbanibulin treatment compared to other treatments were discussed with attendees, as well as current treatment needs of AK patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This article provides an overview of presentations and symposium discussions, summarizing key phase\u2010III results and real\u2010life clinical experience with tirbanibulin shared by dermatologists across Europe.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.19636","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T09:50:40Z","timestamp":1703065840000},"page":"3-15","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of tirbanibulin 1% ointment in actinic keratoses: Data from two phase\u2010<scp>III<\/scp> trials and the real\u2010life clinical practice presented at the European Academy of Dermatology and Venereology Congress 2022"],"prefix":"10.1111","volume":"38","author":[{"given":"G.","family":"Pellacani","sequence":"first","affiliation":[{"name":"Department of Clinical Internal, Anesthesiological, and Cardiovascular Sciences La Sapienza University  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Schlesinger","sequence":"additional","affiliation":[{"name":"Clinical Research Center of the Carolinas  Charleston South Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Therapeutics Clinical Research  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9872-5402","authenticated-orcid":false,"given":"B.","family":"Berman","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Cutaneous Surgery University of Miami Miller School of Medicine  Miami Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of California  Irvine California USA"},{"name":"AboutSkin Dermatology and DermSurgery  Greenwood Village Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. K.","family":"Patel","sequence":"additional","affiliation":[{"name":"Welsh Institute of Dermatology University Hospital Wales  Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kunstfeld","sequence":"additional","affiliation":[{"name":"Dermatology Department Medical University Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Hadshiew","sequence":"additional","affiliation":[{"name":"Derma Koeln  Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. T.","family":"Lear","sequence":"additional","affiliation":[{"name":"Mid Cheshire Hospitals NHS Foundation Trust  Crewe UK"},{"name":"MAHSC, Manchester University  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26071979"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.01.017"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.127"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054989"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13180"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07692.x"},{"issue":"1","key":"e_1_2_14_8_1","first-page":"8","article-title":"Actinic keratosis and non\u2010invasive diagnostic techniques: an update","volume":"6","author":"Casari A","year":"2018","journal-title":"Biomedicine"},{"issue":"4","key":"e_1_2_14_9_1","first-page":"378","article-title":"Spanish adaptation of the European guidelines for the evaluation and treatment of actinic keratosis","volume":"105","author":"Ferr\u00e1ndiz C","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00674-3"},{"issue":"1","key":"e_1_2_14_11_1","article-title":"Cancer risks in solid organ transplant recipients: results from a comprehensive analysis of 72 cohort studies","volume":"9","author":"Huo Z","year":"2020","journal-title":"Onco Targets Ther"},{"key":"e_1_2_14_12_1","volume-title":"StatPearls","author":"Williams GM","year":"2023"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199003000-00006"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20974"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm4061229"},{"issue":"10","key":"e_1_2_14_16_1","first-page":"s4","article-title":"Individual article: safety and tolerability of topical agents for actinic keratosis: a systematic review of phase 3 clinical trials","volume":"20","author":"Rajkumar JR","year":"2021","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024040"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S121323"},{"key":"e_1_2_14_19_1","unstructured":"LangerT.S3\u2010Leitlinie \u201cAktinische Keratose und Plattenepithelkarzinom der Haut\u201d: Leitlinien programm Onkologie Deutsche Krebsgesellschaft Deutsche Krebshilfe [Internet]. 2022 [cited 2023 May 23]. Available from:https:\/\/www.leitlinienprogramm\u2010onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Aktinische_Keratosen_und_PEK\/Version_2\/LL_Aktinische_Keratose_und_PEK_Kurzversion_2.0.pdf"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.056"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.04.013"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2021.07.006"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S374122"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.25251\/skin.5.2.1"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16801"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17184"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.19636","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T09:42:56Z","timestamp":1704361376000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.19636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":25,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1111\/jdv.19636"],"URL":"https:\/\/doi.org\/10.1111\/jdv.19636","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,20]]},"assertion":[{"value":"2023-07-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}